Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$79.78
+$1.03 · +1.31%
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Previous close
$79.78
+$1.03 · +1.31%
Regular session · ET · Market data may be delayed.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Day range
Current $79.78
52-week range
Current $79.78
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
79
Undervalued
Sentiment
66
Bullish
Risk
31
Moderate Risk
Momentum
70
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Day range
Current $79.78
52-week range
Current $79.78
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 677.56M USD | 423.24M USD | 270.26M USD | 220.18M USD | 38.54M USD |
| Cost of goods sold | 307.41M USD | 60.91M USD | 56.52M USD | 22.9M USD | 9.1M USD |
| Gross profit | 370.15M USD | 362.33M USD | 213.74M USD | 197.29M USD | 29.44M USD |
| Research and development | 96.85M USD | 111.62M USD | 76.1M USD | 65.49M USD | 99.3M USD |
| Selling, general, and administrative | 196.27M USD | 168.01M USD | 129.43M USD | 97.95M USD | 85.95M USD |
| Operating expenses | 292.93M USD | 407.95M USD | 238.93M USD | 187.51M USD | 186.08M USD |
| Interest income | 11.65M USD | 9.46M USD | 8.54M USD | 1.25M USD | 97K USD |
| Depreciation and amortization | 1.55M USD | 1.7M USD | 2.34M USD | 2.4M USD | 2.36M USD |
| Operating income | 77.22M USD | −45.62M USD | −25.2M USD | 9.77M USD | −156.64M USD |
| Net income | 59.01M USD | −43.19M USD | 14.08M USD | 183.36M USD | −157.92M USD |
Company facts updated Oct 11, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$86.40
8.30% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
